Detection of tumor-derived DNA mutations in cerebrospinal fluid of patients with primary or metastatic brain tumors
Molecular analysis of cell-free DNA to identify distinct molecular mutational burden and its effect on first-line chemotherapy in patients with NSCLC from a phase III trial